EP0455422A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method of treating or preventing baldness with compositions containing fibroblast growth factor
Assignee: Merck and Co Inc
•
Filing: 1991-04-25
•
Granted: —
•
Expires: 2011-04-25
Abstract
Abstract A method of retarding or reversing baldness which comprises the topical application of compositions containing as at least one of its active in-ingredients fibroblast growth factor (FGF). The FGF may be acidic FGF (aFGF), basic FGF (bFGF), int-2, hst/KS3, FGF-5, FGF-6 or KGF or a combination thereof. The compositions may also include other protein growth factors or hair growth promoting agents combined with FGF.
Inventors
- 👤 Theodore M. Mellin
- 👤 Kenneth A. Thomas, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 02:17
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/64; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1825; A61P; A61P17/00; A61P43/00; A61Q; A61Q7/00
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
35 words
A method of improving the bodily appearance of a person which comprises topically applying to the scalp of said person one or more fibroblast growth factors in an amount effective to treat or prevent alopecia.
Claim 2
Dependent Claim
32 words
The method according to Claim 1 wherein the fibroblast growth factor is selected from the group consisting of acidic fibroblast growth factor, basic fibroblast growth factor, int-2, hst/KS3, FGF-5, FGF-6 or KGF.
Claim 3
Dependent Claim
16 words
The method according to Claim 2 wherein the fibroblast growth factor is acidic fibroblast growth factor.
Claim 4
Dependent Claim
48 words
The method according to Claim 2 or Claim 3 wherein the fibroblast growth factor is co-administered with one or more protein growth factors selected from the group consisting of epidermal growth factor, platelet-derived growth factor, transforming growth factor-alpha, transforming growth factor-beta, insulin-like growth factor-I and insulin-like growth factor-II.
Claim 5
Dependent Claim
39 words
The method according to Claim 2 or Claim 3 wherein the fibroblast growth factor is co-administered with one or more hair growth promoting compounds selected from the group consisting of minoxidil, minoxidil analogs, minoxidil derivatives, anti-androgens and 5α-reductase inhibitors.
Claim 6
Dependent Claim
23 words
The method according to Claim 1 wherein the fibroblast growth factor is topically applied in a pharmaceutical composition containing a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
28 words
The method according to Claim 4 wherein the fibroblast growth factor co-administered with protein growth factor is topically applied in a pharmaceutical composition containing a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
29 words
The method according to Claim 5 wherein the fibroblast growth factor co-administered with hair growth promoting compounds is topically applied in a pharmaceutical composition containing a pharmaceutically acceptable carrier.
Claim 9
Independent Claim
26 words
The method according to any one of Claims 6 to 8 wherein the pharmaceutical composition is a solution, cleaner, cream, gel, lotion, ointment, shampoo or aerosol.
Claim 10
Independent Claim
74 words
A method of improving the bodily appearance of a person which comprises the sequence of steps of: a. the removal of hair plugs from the occipital region of the scalp; b. treating the hair plugs or transplant recipient sites with one or more fibroblast growth factors in an effective stimulatory amount to treat or prevent alopecia; c. implantation and attachment of the treated hair plugs into the vertex or frontal areas of the scalp.
Claim 11
Dependent Claim
34 words
The method according to Claim 10, step b wherein the fibroblast growth factor is selected from the group consisting of acidic fibroblast growth factor, basic fibroblast growth factor, int-2, hst/KS3, FGF-5, FGF-6 or KGF.
Claim 12
Dependent Claim
50 words
The method according to Claim 10, step b or Claim 11 wherein the fibroblast growth factor is co-administered with one or more protein growth factors selected from the group consisting of epidermal growth factor, platelet-derived growth factor, transforming growth factor-alpha, transforming growth factor-beta, insulin-like growth factor-I and insulin-like growth factor-II.
Claim 13
Dependent Claim
41 words
The method according to Claim 10, step b or Claim 11 wherein the fibroblast growth factor is co-administered with one or more hair growth promoting compounds selected from the group consisting of minoxidil, minoxidil analogs, minoxidil derivatives, anti-androgens and 5α-reductase inhibitors.
Claim 14
Dependent Claim
21 words
The use of one or more fibroblast growth factors for the manufacture of a medicament suitable for treating or preventing alopecia.
Claim 15
Dependent Claim
51 words
The use as claimed in Claim 14 wherein the medicament is adapted for co-administration of the fibroblast growth factor with one or more protein growth factors selected from the group consisting of epidermal growth factor, platelet-derived growth factor, transforming growth factor-alpha, transforming growth factor-beta, insulin-like growth factor-I and insulin-like growth factor-II.
Claim 16
Dependent Claim
42 words
The use as claimed in Claim 14 wherein the medicament is adapted for co-administration of the fibroblast growth factor with one or more hair growth promoting compounds selected from the group consisting of minoxidil, minoxidil analogs, minoxidil derivatives, anti-androgens and 5α-reductase inhibitors.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.